FDA advisory committee to review blood-based cancer detection test

An FDA advisory committee is scheduled to review the Galleri blood-based cancer detection test by GRAIL in September despite its clinical trial failing to meet the primary endpoint of statistically significant reduction in late-stage cancers, signalling a potential regulatory reconsideration.

This Wire brief sits within Fusion42's coverage of Health.